Science & Enterprise subscription

Follow us on Twitter

  • Our #podcast is now live ... NPC Members Display Photos At Annual Club Exhibit @pressclubdc #NPCPhotoEx
    about 14 hours ago
  • More Democrats say they're in favor of increased federal spending on scientific research than Republicans, a gap th…
    about 14 hours ago
  • New post on Science and Enterprise: Infographic – Partisan Split Remains on Research Spending #Science #Business
    about 14 hours ago
  • The first participant in a clinical trial received an experimental minimally-invasive brain implant to record brain…
    about 1 day ago
  • New post on Science and Enterprise: Trial Underway Testing Brain-Computer Implant #Science #Business
    about 1 day ago

Please share Science & Enterprise

Say Hello to HelloToken

Hello name tag

(Eviatar Bach, Wikimedia Commons)

25 May 2016. Science & Enterprise, as regular visitors know, is a business and science news blog that tries to make the visiting experience both professional and productive. We’re also a business enterprise, and need to generate income to support our work. We’re starting a feature on Science & Enterprise that we believe will add to our income, while respecting the visitors’ time and intelligence.

The new feature is HelloToken, provided by a start-up enterprise of the same name spun-off from Harvard University. HelloToken  presents brief one-question surveys from sponsors as you join Science & Enterprise. After you choose an answer, the question disappears. That’s it. Questions are unobtrusive and multiple choice; just make your choice.

You can opt out from answering by clicking off the question, but by responding you help keep Science & Enterprise freely available. As part of the deal, we will remove much of our current advertising on posts and pages.

By the way, HelloToken incubated at Harvard’s Innovation Lab or i-Lab, an entrepreneurial center on campus. We reported on i-Lab’s opening in 2011, and just last week told about an i-Lab spin-off enterprise developing diagnostics for HIV infection.

As always, we welcome your feedback. Let us know your comments, pro or con, at

*     *     *

Please share Science & Enterprise ...

Comments are closed.